Evidence map›Paper›PMID 25066726›Full record

ArticleMolecular oncology2014

Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: implications for the anti-tumor barrier concept and treatment.

Jirina Bartkova, Christina E Hoei-Hansen, Katerina Krizova, Petra Hamerlik, Niels E Skakkebæk, Ewa Rajpert-De Meyts, Jiri Bartek

Open access · bronzeAbstract read
In one paragraph

Article in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Pineal germ cell tumors: Two cases with review of histopathologies and biomarkers.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2017
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jirina BartkovaDanish Cancer Society Research Center, Copenhagen, Denmark. Electronic address: jib@cancer.dk.
Christina E Hoei-HansenUniversity Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark; Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark.
Katerina KrizovaDanish Cancer Society Research Center, Copenhagen, Denmark; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Petra HamerlikDanish Cancer Society Research Center, Copenhagen, Denmark.
Niels E SkakkebækUniversity Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.
Ewa Rajpert-De MeytsUniversity Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark. Electronic address: erm@rh.dk.
Jiri BartekDanish Cancer Society Research Center, Copenhagen, Denmark; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Rigshospitalet · DKDanish Cancer Society · DKInstitute of Molecular and Translational Medicine · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The DNA damage response (DDR) machinery becomes commonly activated in response to oncogenes and during early stages of development of solid malignancies, with an exception of testicular germ cell tumors (TGCTs). The active DDR signaling evokes cell death or senescence but this anti-tumor barrier can be breached by defects in DDR factors, such as the ATM-Chk2-p53 pathway, thereby allowing tumor progression. The DDR barrier is strongly activated in brain tumors, particularly gliomas, due to oxidative damage and replication stress. Here, we took advantage of rare human primary intracranial germ cell tumors (PIGCTs), to address the roles of cell-intrinsic factors including cell of origin, versus local tissue environment, in the constitutive DDR activation in vivo. Immunohistochemical analysis of 7 biomarkers on a series of 21 PIGCTs (germinomas and other subtypes), 20 normal brain specimens and 20 glioblastomas, revealed the following: i) The overall DDR signaling (γH2AX) and activation of the ATM-Chk2-p53 pathway were very low among the PIGCTs, reminiscent of TGCTs, and contrasting sharply with strong DDR activation in glioblastomas; ii) Except for one case of embryonal carcinoma, there were no clear aberrations in the ATM-Chk2-p53 pathway components among the PIGCT cohort; iii) Subsets of PIGCTs showed unusual cytosolic localization of Chk2 and/or ATM. Collectively, these results show that PIGCTs mimic the DDR activation patterns of their gonadal germ cell tumor counterparts, rather than the brain tumors with which they share the tissue environment. Hence cell-intrinsic factors and cell of origin dictate the extent of DDR barrier activation and also the ensuing pressure to select for DDR defects. Our data provide conceptually important insights into the role of DNA damage checkpoints in intracranial tumorigenesis, with implications for the differential biological responses of diverse tumor types to endogenous stress as well as to genotoxic treatments such as ionizing radiation or chemotherapy.

Indexed as

AdolescentAdultAtaxia Telangiectasia Mutated ProteinsBrain NeoplasmsCheckpoint Kinase 2ChildChild, PreschoolDNA DamageFemaleGangliogliomaGlioblastomaHumansImmunohistochemistryInfantInfant, NewbornMaleAtaxia Telangiectasia Mutated ProteinsATM protein, humanCheckpoint Kinase 2CHEK2 protein, humanATM-Chk2-p53 pathwayDNA damage signalingGliomasIntracranial germ cell tumorsTesticular germ cell neoplasms

Identifiers

PMID25066726
PMCPMC5528598
OpenAlexW1984830467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.